Skip to content

Prevention of Complications Due to Autonomic Dysreflexia in SCI Individuals

Risk Level Determination of Vascular Complications Due to Autonomic Dysreflexia in Spinal Cord Injured Individuals

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05024487
Enrollment
40
Registered
2021-08-27
Start date
2023-01-01
Completion date
2023-12-31
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Dysreflexia, Spinal Cord Injuries

Keywords

Autonomic Nervous System, Spinal Cord Injury, Prevention

Brief summary

Autonomic dysreflexia (AD) is a syndrome of unbalanced response of the sympathetic system to noxious stimuli below the level of spinal cord injury (SCI), characterized by paroxysmal hypertension. Mostly, it is combined with symptoms such as pounding headache, slowed heart rate, and upper body flushing, but it can also be asymptomatic. When resulting in hypertensive crisis, it can be life-threatening and result in seizures, cardiac arrest, retinal or subarachnoid hemorrhages, stroke, and even death. The aim of this study is to determine the risk level of vascular complications in SCI people by correlating the clinical symptoms with their individual perception during AD triggered below the level of injury.

Detailed description

After spinal cord injury, the disruption of descending vasomotor pathways to sympathetic neurons causes their hyperexcitability. When irritated by noxious stimuli below the level of injury, a massive sympathetic reflex is triggered, causing widespread vasoconstriction. If the neurological level of injury is at or above T6, this vasoconstriction can lead to progressive hypertension possibly involving the splanchnic vessels. In response to hypertension, the baroreflex system lowers blood pressure by reducing heart rate and decreasing the activity of sympathetic neurons. However, a decrease in peripheral vascular resistance below the injury level does not occur because of the disruption of descending vasomotor pathways to sympathetic neurons. Thus, hypertension persists until the triggering stimulus is removed. Hypertensive crises can result in vascular complications like cardiac arrest, retinal or subarachnoid hemorrhages, stroke, and even death. Vasodilatation above the lesion level is accompanied by characteristic signs and symptoms such as upper body flushing and sweating, and a pounding headache. Sometimes bradyarrhythmia, seizures, nausea, or anxiety can occur. Unfortunately, AD can take place asymptomatically in almost 40 %. These asymptomatic individuals are at high risk of life-threatening complications mentioned above. The most frequent AD triggers are overfilled bladder or bowel. Nevertheless, it can be any irritating stimuli below the level of injury, i.e., skin lacerations, ingrown toenails, or pressure sores. Higher intensity of perception of clinical symptoms accompanying AD decreases the risk of vascular complications. People who perceive subjective signs of AD even in slightly elevated blood pressure can eliminate irritating stimuli or use an antihypertensive medication and thus avoid life-threatening complications. On contrary, people who cannot perceive the signs intensely enough are at a significantly higher risk of vascular complications. The aim of this study is to determine the risk level of vascular complications in SCI people. The AD will be triggered below the injury level so that the clinical symptoms can be correlated with their subjective individual perception. Moreover, the development of a method allowing capturing AD episodes in individuals without subjective signs is intended.

Interventions

DIAGNOSTIC_TESTClinical Examination

Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.

Sponsors

Assoc. Prof. Jiri Kriz, MD, PhD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 70 years old female and male patients * People in chronic phase (more than 12 months) after traumatic or ischemic spinal cord lesion * People with Neurological Level of Injury C3-T6 and ASIA Impairment Scale A-B according to ISNCSCI * Written informed consent

Exclusion criteria

* People with acute infection or other suddenly incurred complication

Design outcomes

Primary

MeasureTime frameDescription
Blood pressure monitoringDuring the interventionContinuous blood pressure and heart rate monitoring will be recorded using Finapres device. The risk level will be determined according to the value of systolic blood pressure (SBP): 1. Low risk - SBP to 150 mmHg 2. Moderate risk - SBP 150-200 mmHg 3. High risk - SBP above 200 mmHg

Secondary

MeasureTime frameDescription
Dermal sweatingDuring the interventionWrist sweating will be monitored using a measure of dermal resistance with range 0-5 MΩ (difference 0,1 kΩ, accuracy 0,15 %) and 5-32 MΩ (difference 10 kΩ, accuracy 1 %) and sampling frequency 10 second. Regarding the AD symptoms, level of dermal resistance decrease corresponds to increase of sweating.
Assessment of symptomsDuring the interventionSubjective individual symptoms are divided into three groups, according to their severity (minimum value: mild symptoms, maximum: strong symptoms): 1. Mild symptoms - shivers on the nape or on the back 2. Moderate symptoms - sweating on the forehead, neck or upper extremities 3. Strong symptoms - pounding headache, nausea
ADFSCI questionnaireDuring the interventionThe ADFSCI (Autonomic Dysfunction Following Spinal Cord Injury) questionnaire provides information about individual symptoms of blood pressure (BP) instability. The ADFSCI is a 24-item questionnaire consisting of four parts: demographics, medication, AD, and hypotension. The AD and hypotension parts include 10 and 7 items, respectively, each using a 5-point scale to score the frequency and severity of hyper- or hypotensive symptoms with a range of 0 ∼ 204 (highest BP instability) points.

Countries

Czechia

Contacts

Primary ContactJiri Kriz, MD, PhD
jiri.kriz@fnmotol.cz+420224439207
Backup ContactRenata Hakova, MD
renata.hakova@fnmotol.cz+420224439265

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026